The Effect of Recombinant Human Erythropoietin on Bacterial Growth: A Dual-Edged Sword
-
Published:2018-11-13
Issue:2
Volume:5
Page:81-90
-
ISSN:2296-9381
-
Container-title:Kidney Diseases
-
language:en
-
Short-container-title:Kidney Dis
Author:
Mittal Ankur,
Singh Vandana,
Chowdhary Sheemona,
Moideen Amal,
Kumar Deepak,
Maniar Kunal,
Bhattacharyya Rajasri,
Banerjee DibyajyotiORCID
Subject
Materials Chemistry
Reference27 articles.
1. Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013 Oct;40(5):302–9.
2. Cazzola M. How and when to use erythropoietin. Curr Opin Hematol. 1998 Mar;5(2):103–8.
3. Segal GM, Eschbach JW, Egrie JC, Stueve T, Adamson JW. The anemia of end-stage renal disease: hematopoietic progenitor cell response. Kidney Int. 1988 May;33(5):983–8.
4. Grote Beverborg N, Verweij N, Klip IT, van der Wal HH, Voors AA, van Veldhuisen DJ, et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS One. 2015 Apr;10(4):e0125215.
5. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al.; EPO Critical Care Trials Group. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002 Dec;288(22):2827–35.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献